Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial NU EM11B03

Title
Randomized phase II trial of trastuzumab or EVEROLIMUS in hormone-refractory metastatic breast cancer
Principal Investigator
Virginia Kaklamani
Details
  • Status: CLOSED
  • Study Type: Therapeutic, Treatment
  • Protocol No:.NU EM11B03
Purpose
The purpose of this study is to investigate if trastuzumab or everolimus is effective for breast cancers that are no longer controlled with (resistant to) hormonal therapies, and have small to moderate amounts of HER2/neu.
Overview
Breast cancers that become resistant to hormonal therapies, such as tamoxifen and aromatase inhibitors, often have small to moderate amounts of a protein, called HER2/neu. Trastuzumab is an antibody which targets this HER2/neu protein. Participants in this study have breast cancer that did not express high levels of HER2/neu when they were diagnosed, which is why they were not already treated with trastuzumab. Agents that target another protein in breast cancer cells called mTOR, such as everolimus, have been noted to make cancer cells more sensitive to hormonal therapies and trastuzumab. There is no standard of care for the disease once it becomes resistant to hormonal therapy, and many patients are treated with chemotherapy. Based on laboratory findings, it is believed that trastuzumab, in combination with the most recent hormonal therapy received, may be effective in breast cancers that are 1) no longer controlled with hormonal therapies and 2) have small to moderate levels of HER2/neu. Everolimus targets a protein called mTOR which appears to become more active in breast cancers that are no longer controlled by hormonal therapies.
Eligibility
Some of the eligibility criteria include:
  • Participants must be at least 18 years of age.
  • Participants must have breast cancers that become resistant to hormonal therapies.
  • Participants must not have had prior treatment with trastuzumab or other HER2-directed therapies or with an mTOR inhibitor.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
In this study participants will be randomly chosen to receive either trastuzumab alone or everolimus alone. Trastuzumab is a liquid, which will be infused directly into the vein through a tube. Participants will have to be at the clinic to receive trastuzumab. Everolimus is a pill that will be taken every day.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

last updated: 24-Oct-14 04:19 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.